Orthocell Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
691.40
790.40
666.50
529.80
619.20
Cost of Goods Sold (COGS) incl. D&A
2,111.30
3,755.80
3,549.80
438.10
382.10
Gross Income
1,419.90
2,965.40
2,883.30
91.70
237.10
SG&A Expense
1,885.80
2,835.00
2,930.00
6,763.90
8,529.90
EBIT
3,305.60
5,800.40
5,813.40
6,672.20
8,292.80
Non Operating Income/Expense
577.90
776.50
458.90
511.00
265.00
Pretax Income
2,712.60
4,900.50
5,292.60
6,125.40
8,009.30
Income Tax
530.40
1,157.80
1,507.80
1,948.00
2,252.20
Consolidated Net Income
2,182.20
3,742.70
3,784.90
4,177.40
5,757.10
Net Income
2,182.20
3,742.70
3,784.90
4,177.40
5,757.10
Net Income After Extraordinaries
2,182.20
3,742.70
3,784.90
4,177.40
5,757.10
Net Income Available to Common
2,182.20
3,742.70
3,784.90
4,177.40
5,757.10
EPS (Basic)
0.61
0.05
0.04
0.04
0.05
Basic Shares Outstanding
82,500.00
75,657.10
87,965.30
96,958.90
105,726.80
EPS (Diluted)
0.03
0.05
0.04
0.04
0.05
Diluted Shares Outstanding
82,500.00
75,657.10
87,965.30
96,958.90
105,726.80
EBITDA
3,267.80
5,741.10
5,713.20
6,524.40
8,099.50
Non-Operating Interest Income
15.10
123.40
61.80
35.70
18.50

About Orthocell

View Profile
Address
Building 191
Murdoch Western Australia (WA) 6150
Australia
Employees -
Website http://www.orthocell.com.au
Updated 07/08/2019
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. Its products include CelGro which derives collagen medical device for soft tissue repair; and Antologous Tenocyte Implantation (Ortho-ATI) for chronic, treatment resistant tendon injuries. The company was founded by Paul Anderson and Min Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.